# Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

> **NCT00220740** · PHASE3 · COMPLETED · sponsor: **Grifols Therapeutics LLC** · enrollment: 117 (actual)

## Conditions studied

- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

## Interventions

- **DRUG:** Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified
- **DRUG:** Albumin (Human) 25%, United States Pharmacopeia (USP)

## Key facts

- **NCT ID:** NCT00220740
- **Lead sponsor:** Grifols Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2016-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00220740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00220740, "Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00220740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*